Polatuzumab Vedotin: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HIRA (South Korea), NICE (England) and SMC (Scotland), among others, recommended or restricted polatuzumab vedotin, while CIPM (Spain), DMC (Denmark) and PBAC (Australia) did not recommend it.
On the same population the two systems disagree outright: NICE (England) recorded restricted in TA874, while PBAC (Australia) recorded not recommended for “Diffuse large B-Cell lymphoma”.
Assessment has run over 6.8 years, from 2019 at PBAC (Australia) to 7 May 2026 at HIRA (South Korea).
NYE METODER (Norway) changed its position: recommended on 17 Jan 2021, not recommended by 16 Jun 2024.
No assessment is on file from HAS (France), PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
The file is active: 11 of 23 records date from 2023 or later.
Against its own class, polatuzumab vedotin is an outlier: 47% of its decisive outcomes were positive, where molecules sharing ATC class L01F average 73%.
7 distinct indication wordings are recorded for polatuzumab vedotin by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 23 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess polatuzumab vedotin, in 2019; HIRA (South Korea) did not open a file until 7 May 2026 — a wide spread of 6.8 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 7 years in total.
Restriction is doing real work here: 5 of 17 decisive outcomes narrowed polatuzumab vedotin to a subgroup rather than accepting or refusing it outright, at AOTMIT (Poland), NICE (England) and SMC (Scotland) among others.
9 of the 13 agencies here assessed polatuzumab vedotin more than once, CIPM (Spain) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
polatuzumab vedotin has been through 13 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for polatuzumab vedotin reads 9 not recommended, 5 restricted, 3 recommended and 3 no benefit, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| G-BA (Germany) | 20 Jun 2024 | Polivy — benefit assessment §35a | added benefit: not proven | source |
| NYE METODER (Norway) | 16 Jun 2024 | I kombinasjon med rituksimab, syklofosfamid, doksorubicin og prednison (R-CHP), indisert for behandling av voksne pasien… | not introduced | source |
| CIPM (Spain) | 22 May 2024 | Indicaciones terapéuticas autorizadas: Polivy en combinación con bendamustina y rituximab está indicado para el tratamie… | not financed by the SNS · art. 92 c, d | source |
| SMC (Scotland) | 10 Jul 2023 | In combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) … | accepted | source |
| AOTMIT (Poland) | 28 May 2021 | Polivy reimbursement recommendation | recommended conditionally | source |
18 further decisions for polatuzumab vedotin, across 13 agencies, are not shown here. They include the most recent record on file, 7 May 2026 from HIRA (South Korea); its outcome is in the subscriber dataset. They link to 17 further source documents.
Related molecules
- epcoritamab — divergent outcome (not recommended vs recommended) on a shared indication
- axicabtagene ciloleucel — divergent outcome (not recommended vs recommended) on a shared indication
- tisagenlecleucel — divergent outcome (not recommended vs recommended) on a shared indication
- glofitamab — divergent outcome (not recommended vs recommended) on a shared indication
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
Coverage: 23 decisions for polatuzumab vedotin from 13 agencies, 2019 to 2026. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.